Nancy Butkiewicz
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Hepatitis C virus research, HIV/AIDS drug development and treatment, Hepatitis B Virus Studies, Monoclonal and Polyclonal Antibodies Research, Biochemical and Molecular Research
Most-Cited Works
- → SCH 503034, a Mechanism-Based Inhibitor of Hepatitis C Virus NS3 Protease, Suppresses Polyprotein Maturation and Enhances the Antiviral Activity of Alpha Interferon in Replicon Cells(2006)316 cited
- → Discovery of (1 R ,5 S )- N -[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2( S )-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2( S )-carboxamide (SCH 503034), a Selective, Potent, Orally Bioavailable Hepatitis C Virus NS3 Protease Inhibitor: A Potential Therapeutic Agent for the Treatment of Hepatitis C Infection(2006)278 cited
- → Enhancement of Hepatitis C Virus NS3 Proteinase Activity by Association with NS4A-Specific Synthetic Peptides: Identification of Sequence and Critical Residues of NS4A for the Cofactor Activity(1996)59 cited
- → I. Novel HCV NS5B polymerase inhibitors: Discovery of indole 2-carboxylic acids with C3-heterocycles(2011)49 cited
- → Amantadine and Rimantadine Have No Direct Inhibitory Effects against Hepatitis C Viral Protease, Helicase, ATPase, Polymerase, and Internal Ribosomal Entry Site–Mediated Translation(2000)44 cited
- → Potent 7-Hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic Acid-Based Macrocyclic Inhibitors of Hepatitis C Virus NS3 Protease(2005)43 cited
- → Virus-Specific Cofactor Requirement and Chimeric Hepatitis C Virus/GB Virus B Nonstructural Protein 3(2000)43 cited
- → Structure of Sch 68631: A new hepatitis C virus proteinase inhibitor from Streptomyces sp.(1996)40 cited
- → Novel Potent Hepatitis C Virus NS3 Serine Protease Inhibitors Derived from Proline-Based Macrocycles(2006)38 cited
- → Two antiviral compounds from the plant Stylogne cauliflora as inhibitors of HCV NS3 protease(2003)36 cited